Observational studyVirology journal2025
Risk of HBV transmission from HBcAb-positive grafts in pediatric liver transplantation: a real-world prospective cohort study.
Observational study in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe utilization of liver grafts from hepatitis B core antibody (HBcAb)-positive donors is relatively common in regions with high hepatitis B virus (HBV) prevalence. This practice poses a potential risk of HBV transmission. However, the impact of these grafts on pediatric liver transplant recipients is not well-established.
methodTo address these knowledge gaps, we conducted a prospective observational cohort study to assess the risk of post-transplant HBV transmission in pediatric recipients of HBcAb-positive grafts. Hepatitis B serology and liver tissue analyses for HBV DNA were performed during post-transplantation follow-up of 188 pediatric recipients.
resultsIn the cohort study, 43 pediatric recipients (22.9%) received HBcAb-positive grafts, while 145 (77.1%) received HBcAb-negative grafts. Over a median follow-up of 43 weeks, 10 recipients (5.3% of the total cohort) developed HBV infection. The cumulative incidence of de novo HBV infection was significantly higher in recipients of HBcAb-positive grafts (18%, 95% CI: 5-31) compared to recipients of HBcAb-negative grafts (3%, 95% CI: 0-6, p < 0.05). Notably, higher levels of hepatitis B surface antibody (HBsAb ≥ 100mIU/ml) in pediatric recipients were associated with a significantly reduced risk of post-transplant de novo HBV infection (p < 0.05).
conclusionHBcAb-positive grafts substantially increase HBV transmission risk in pediatric liver transplantation. Elevated HBsAb titers may mitigate infection severity, while occult HBV infections require vigilant monitoring. Strategic enhancement of recipient HBsAb levels and optimized prophylactic protocols are critical for improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.